• Available and Emerging Therapies for Progressive/Recurrent ROS1-Altered Advanced NSCLC

  • Sep 6 2024
  • Length: 14 mins
  • Podcast

Available and Emerging Therapies for Progressive/Recurrent ROS1-Altered Advanced NSCLC

Listen for free

View show details

  • Summary

  • In this episode, listen to Alice T. Shaw, MD, PhD, and Jessica J. Lin, MD, share their thoughts on the available and emerging clinical data for second-line and beyond treatments in patients with recurrent ROS1-altered advanced NSCLC including:

    • Assessing ROS1-TKI resistance mutations with tumor and liquid biopsies in patients with ROS1-altered advanced NSCLC
    • Previous TKI-treated cohort from the TRIDENT-1 study: efficacy of repotrectinib in patients with recurrent ROS1-altered NSCLC and measurable baseline brain metastases
    • Phase II TRUST-1 trial of taletrectinib: activity in patients with known ROS1 G2032R resistance mutation ROS1-altered advanced NSCLC
    • The global phase I/II ARROS-1 study of zidesamtinib (NVL-520): safety summary in patients with ROS1-altered advanced NSCLC

    Program faculty:

    Jessica J. Lin, MD
    Attending Physician
    Massachusetts General Hospital
    Associate Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

    Alice T. Shaw, MD, PhD
    Chief, Strategic Partnerships
    Attending Physician, Thoracic Oncology
    Dana-Farber Cancer Institute
    Harvard Medical School
    Boston, Massachusetts

    Resources:
    To download the slides associated with this podcast discussion, please visit the program page.
    Show more Show less
Show more Show less

What listeners say about Available and Emerging Therapies for Progressive/Recurrent ROS1-Altered Advanced NSCLC

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available